ERRATUM

Open Access



Erratum to: The evidence on tiotropium bromide in asthma: from the rationale to the bedside

Dejan Radovanovic¹, Pierachille Santus¹, Francesco Blasi² and Marco Mantero^{2*}

Erratum

After publication of the Review article [1] it was brought to our attention that the sentence at the bottom of the section entitled Tiotropium bromide (pag 5) must be corrected as follows: "Following positive large efficacy and safety trials in asthma, in 2014 the European Medicines Agency has extended the indication of tiotropium Respimat[®] at a dose of 5 μ g once (delivered in two inhalation of 2.5 μ g each) to patients with asthma, which was also approved in more than 50 countries, including Japan. In September 2015 the Food and Drug Administration confirmed the same indication, but with a dosage of 2.5 μ g once daily (delivered in two inhalation of 1.25 μ g each); the latter being extended for patients aged 6 and older since 16th February 2017."

Author details

¹Department of Biomedical and Clinical Sciences (DIBIC), University of Milan, Pulmonary Unit, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milan, Italy. ²Department of Pathophysiology and Transplantation, University of Milan, Cardio-thoracic unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Received: 17 May 2017 Accepted: 19 May 2017 Published online: 01 June 2017

References

 Radovanovic D, Santus P, Blasi F, Mantero M. The evidence on tiotropium bromide in asthma: from the rationale to the bedside. Multidiscipl Respir Med. 2017;12:12. doi:10.1186/s40248-017-0094-3.

* Correspondence: marco.mantero@unimi.it

²Department of Pathophysiology and Transplantation, University of Milan, Cardio-thoracic unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy Full list of author information is available at the end of the article



© The Author(s). 2017 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.